Format

Send to

Choose Destination
Health Aff (Millwood). 2015 Feb;34(2):203-9. doi: 10.1377/hlthaff.2014.0975.

Biomedical innovation in the era of health care spending constraints.

Author information

1
James C. Robinson (james.robinson@berkeley.edu) is the Leonard D. Schaeffer Professor of Health Economics and director of the Berkeley Center for Health Technology, School of Public Health, at the University of California, Berkeley.

Abstract

Insurers, hospitals, physicians, and consumers are increasingly weighing price against performance in their decisions to purchase and use new drugs, devices, and other medical technologies. This approach will tend to affect biomedical innovation adversely by reducing the revenues available for research and development. However, a more constrained funding environment may also have positive impacts. The passing era of largely cost-unconscious demand fostered the development of incremental innovations priced at premium levels. The new constrained-funding era will require medical technology firms to design their products with the features most valued by payers and patients, price them at levels justified by clinical performance, and manage distribution through organizations rather than to individual physicians. The emerging era has the potential to increase the social value of innovation by focusing industry on design, pricing, and distribution principles that are more closely aligned with the preferences-and pocketbooks-of its customers.

KEYWORDS:

Cost of Health Care; Insurance Coverage < Insurance; Legal/Regulatory Issues; Medical technology; Pharmaceuticals

PMID:
25646099
DOI:
10.1377/hlthaff.2014.0975
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center